Q4 2024 Earnings Call Transcript February 13, 2025 Operator: Good morning, and welcome to Agios’ Fourth Quarter 2024 ...

If there were a do-it-all nutrient award, it might go to magnesium. The humble mineral plays a critical role in helping your body function successfully. “Aside from being a component of our ...

USA-based Agios Pharmaceuticals has announced that the ACTIVATE-Kids Phase III study of mitapivat in children aged 1 to <18 ...

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to ...

ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –– ...

Presented Phase 1 clinical results on tebapivat (AG-946) in patients with sickle cell disease at ASH 2024. Pediatric Pyruvate Kinase (PK) Deficiency: Reported in a separate press release today, ...

Vitamin deficiency due to hair loss (alopecia) may occur with deficiencies in vitamins B, D, C, and E, as well as with certain minerals like iron, selenium, and zinc. The complex roles of nutritional ...

To investigate whether the Cdc2-like kinase 2 (CLK2) is expressed in hypothalamic ... 12 h-fasted mice were injected (i.p.) with sodium pyruvate (2 g kg −1) and blood samples were ...

135 This metabolic abnormality can be partially corrected by the agent dichloroacetate, which inhibits pyruvate dehydrogenase kinase, the enzyme that phosphorylates and inactivates pyruvate ...

DCA is a targeted therapy that inhibits Pyruvate Dehydrogenase Kinase (PDK) to stimulate residual Pyruvate Dehydrogenase Complex (PDC) activity and increase energy (ATP) production by mitochondria.

DCA will be used with a proprietary genetic test to treat an orphan pediatric mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency (PDCD) 1. The FDA granted Priority Review ... DCA is a ...